Wedbush maintains Janux Therapeutics at Outperform, raises price target to $40 from $36
Займёт меньше минуты
Wedbush maintained Janux Therapeutics at Outperform and raised its price target to $40 from $36, an 11.1% increase.
The price target implies an upside of 149.1% from the Nov 5 close of $16.06.
Explore more price target data and ratings for Janux Therapeutics on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
Читать статью полностью
Получите безграничный доступ к аналитическим материалам и всем другим статьям на TradingView.